- In November 2024, Dr. Reddy’s Laboratories launched India’s first immuno-oncology drug designed to treat a rare form of head and neck cancer This launch marks a significant advancement in cancer treatment options available in India and highlights the company’s commitment to innovative therapies aimed at improving patient outcomes
- In December 2023, Kadcyla by F. Hoffmann-La Roche Ltd marked a ground-breaking achievement of introducing the first targeted therapy to demonstrate a substantial overall survival benefit for individuals with HER2-positive early-stage breast cancer with residual invasive disease following neo - adjuvant treatment
- In December 2023, F. Hoffmann-La Roche Ltd reported favorable Phase III outcomes for the inavolisib combination in individuals with advanced hormone receptor-positive, HER2-negative breast cancer and a PIK3CA mutation. This contributed to Roche's recognition as one of the most sustainable pharmaceutical companies
- In February 2023, AstraZeneca received approval in the European Union (EU) for the tablet formulation of Calquence (acalabrutinib) in the treatment of Chronic Lymphocytic Leukaemia (CLL) in adult patients. This helped the company enhance its market presence and contribute to its revenue growth
- In October 2022, AstraZeneca's combination of Imjudo (tremelimumab) and Imfinzi (durvalumab) has gained US approval for treating unresectable hepatocellular carcinoma (HCC), the most prevalent type of liver cancer in adults. This approval may lead to increased market share, improved revenue streams, and further established AstraZeneca as a key player in the field of cancer therapeutics
- In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This helped the company strengthen its product portfolio
